Related references
Note: Only part of the references are listed.Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24 577 first-degree relatives of 11 039 patients with myeloproliferative neoplasms in Sweden
Ola Landgren et al.
BLOOD (2008)
The emerging landscape of breast cancer susceptibility
Michael R. Stratton et al.
NATURE GENETICS (2008)
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
Jeffrey C. Barrett et al.
NATURE GENETICS (2008)
Subclonal phylogenetic structures in cancer revealed by ultra-deep sequencing
Peter J. Campbell et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis
Linda M. Scott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
JAK2(V617F): prevalence in a large Chinese hospital population
Xuesong Xu et al.
BLOOD (2007)
Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders
Ross L. Levine et al.
NATURE REVIEWS CANCER (2007)
Mechanisms of disease: The myeloproliferative disorders
Peter J. Campbell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
MPLW515L is anovel somatic activating mutation in myelofibrosis with myeloid metaplasia
Yana Pikman et al.
PLOS MEDICINE (2006)
Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders
Christine Bellanne-Chantelot et al.
BLOOD (2006)
The kinetics of clonal dominance in myeloproliferative disorders
SN Catlin et al.
BLOOD (2005)
Share Paper
